Eribulin
As of the edition of 20 October 2026, Eribulin is a small molecule: marketed, first approved in 2010 (US); acts on TUBB, TUBB1 and TUBB2A and 6 more; US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Halaven
- First approved
- 15 November 2010 (US)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Baxter Healthcare; 2 holders in all
- Registered trials
- 173, 25 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Hormones; Lungs and airways
US protection
US protection ended in 2026.
The last listed US exclusivity ended in 2026. The application that gives this date is held by Eisai.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
9 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product9 company-target rows are on route B because of Eribulin.
See the 9 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 6 | 0 | 1 |
| Phase 1 | 33 | 21 | 4 | 7 |
| Phase 2 | 108 | 52 | 24 | 15 |
| Phase 3 | 17 | 7 | 6 | 2 |
| Phase 4 | 4 | 3 | 0 | 0 |
| All trials | 173 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eisai | Originator and Lead sponsor of trials | 2003 to now |
| Baxter Healthcare | Applicant | 2025 to now |